MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

Authors

P. de la Puente, Washington University School of Medicine in St. Louis
B. Muz, Washington University School of Medicine in St. Louis
A. Jin, Washington University School of Medicine in St. Louis
F. Azab, Washington University School of Medicine in St. Louis
M. Luderer, Washington University School of Medicine in St. Louis
N. N. Salama, St. Louis College of Pharmacy
A. K. Azab, Washington University School of Medicine in St. Louis

Document Type

Letter to the Editor

Publication Title

Blood Cancer Journal

DOI

10.1038/BCJ.2016.7

Publication Date

1-1-2016

Recommended Citation

de la Puente, P.; Muz, B.; Jin, A.; Azab, F.; Luderer, M.; Salama, N. N.; and Azab, A. K., "MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma" (2016). Pharmaceutical and Administrative Sciences Faculty Publications. 237. https://doi.org/10.1038/BCJ.2016.7
https://collections.uhsp.edu/pharm-admin-sciences_pubs/237